Fishingboy personal page - To The Moon

Fishingboy

Fishingboy

No personal profile

17Follow

2Followers

0Topic

0Badge

2021-03-10

$AYRO, Inc.(AYRO)$Lol

2021-06-25

Good to think about it!

Sorry, the original content has been removed

2021-06-25

That’s good news

Sorry, the original content has been removed

2021-03-10

Must be careful

Investors blinded by over-optimism on vaccine rollout must see these risks, warns economist

2021-08-05

$Bitfarms Ltd.(BITF)$Set the wrong buy limit but I guess 10% profit is still better than nothing

2021-03-15

Indeed this will be interesting to watch!

Pinduoduo, Nike,AMD, Lennar, and Other Stocks for Investors to Watch This Week

2021-03-12

Yes indeed that is true

Sorry, the original content has been removed

2021-03-11

$Sea Ltd(SE)$Was a little disappointed that we didn’t hold the slope up yesterday but I guess it would be good to spend more time in consolidation mode. It could be difficult to see but will be healthier in the long run. Hoping for more sustained upside action in the months to come!

2021-03-09

$Sea Ltd(SE)$My only regret is not buying when Shopee launched in Singapore a few years ago. They’re actually doing quite well in terms of public sentiment and I think they’ll do well compared to direct competitors

2021-03-09

Go J&J!

J&J 'under stress' to meet EU second-quarter vaccine supply goal - source

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3578051801807213","uuid":"3578051801807213","gmtCreate":1614957777979,"gmtModify":1615127155737,"name":"Fishingboy","pinyin":"fishingboy","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":17,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":899885493,"gmtCreate":1628173737712,"gmtModify":1703502597837,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BITF\">$Bitfarms Ltd.(BITF)$</a>Set the wrong buy limit but I guess 10% profit is still better than nothing&nbsp;","listText":"<a href=\"https://laohu8.com/S/BITF\">$Bitfarms Ltd.(BITF)$</a>Set the wrong buy limit but I guess 10% profit is still better than nothing&nbsp;","text":"$Bitfarms Ltd.(BITF)$Set the wrong buy limit but I guess 10% profit is still better than nothing","images":[{"img":"https://static.tigerbbs.com/803c9b4ab887314e0ebb7722c4770c51","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899885493","isVote":1,"tweetType":1,"viewCount":1366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":125013748,"gmtCreate":1624636375684,"gmtModify":1703842504505,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"Good to think about it!","listText":"Good to think about it!","text":"Good to think about it!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/125013748","repostId":"2146079086","repostType":4,"isVote":1,"tweetType":1,"viewCount":2827,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126867391,"gmtCreate":1624551772513,"gmtModify":1703840275896,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"That’s good news","listText":"That’s good news","text":"That’s good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126867391","repostId":"2145704596","repostType":4,"isVote":1,"tweetType":1,"viewCount":1781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126800775,"gmtCreate":1624549531097,"gmtModify":1703840196606,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>Not sure about you but I see a W pattern on the daily with an upside target of around usd400. Might dip back to the usd200++ level if it fails.Sea Group looking bullish but they should lookto&nbsp;sustain&nbsp;growth.Not here to predict but to prepare.*my opinion, never financial advice*","listText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>Not sure about you but I see a W pattern on the daily with an upside target of around usd400. Might dip back to the usd200++ level if it fails.Sea Group looking bullish but they should lookto&nbsp;sustain&nbsp;growth.Not here to predict but to prepare.*my opinion, never financial advice*","text":"$SEA LTD(SE)$Not sure about you but I see a W pattern on the daily with an upside target of around usd400. Might dip back to the usd200++ level if it fails.Sea Group looking bullish but they should lookto sustain growth.Not here to predict but to prepare.*my opinion, never financial advice*","images":[{"img":"https://static.tigerbbs.com/d3e90c1fec4c1674412f816421694e72","width":"1170","height":"2532"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126800775","isVote":1,"tweetType":1,"viewCount":2861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":325047787,"gmtCreate":1615854124149,"gmtModify":1704787441210,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"Go cathie!!","listText":"Go cathie!!","text":"Go cathie!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325047787","repostId":"1170973847","repostType":4,"isVote":1,"tweetType":1,"viewCount":1546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325047668,"gmtCreate":1615854105854,"gmtModify":1704787441371,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"Please be safe!","listText":"Please be safe!","text":"Please be safe!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325047668","repostId":"1145894014","repostType":4,"repost":{"id":"1145894014","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1615845475,"share":"https://ttm.financial/m/news/1145894014?lang=en_US&edition=fundamental","pubTime":"2021-03-16 05:57","market":"us","language":"en","title":"Germany, Italy, France suspend AstraZeneca shots amid safety fears, disrupting EU vaccinations","url":"https://stock-news.laohu8.com/highlight/detail?id=1145894014","media":"Reuters","summary":"Germany, France and Italy said on Monday they would suspend AstraZeneca COVID-19 shots after several","content":"<p>Germany, France and Italy said on Monday they would suspend AstraZeneca COVID-19 shots after several countries reported possible serious side-effects, but the World Health Organization&nbsp;(WHO) said there was no proven link and people should not panic.</p>\n<p>Still, the decision by the European Union’s three biggest countries to put inoculations with the AstraZeneca shot on hold threw the already struggling vaccination campaign in the 27-nation EU into disarray.</p>\n<p>Denmark and Norway stopped giving the shot last week after reporting isolated cases of bleeding, blood clots and a low platelet count. Iceland and Bulgaria followed suit and Ireland and the Netherlands announced suspensions on Sunday.</p>\n<p>Spain will stop using the vaccine for at least 15 days, Cadena Ser radio reported, citing unnamed sources.</p>\n<p>The top WHO scientist reiterated on Monday that there have been no documented deaths linked to COVID-19 vaccines.</p>\n<p>“We do not want people to panic,” Soumya Swaminathan said on a virtual media briefing, adding there has been no association, so far, pinpointed between so-called “thromboembolic events” reported in some countries and COVID-19 shots.</p>\n<p>WHO chief Tedros Adhanom Ghebreyesus said an advisory committee meeting on AstraZeneca would be held on Tuesday. EU medicines regulator EMA will also convene this week to assess the information gathered into whether the AstraZeneca shot contributed to thromboembolic events in those inoculated.</p>\n<p>The moves by some of Europe’s largest and most populous countries will deepen concerns about the slow rollout of vaccines in the region, which has been plagued by shortages due to problems producing vaccines, including AstraZeneca’s.</p>\n<p>Germany warned last week it was facing a third wave of infections, Italy is intensifying lockdowns and hospitals in the Paris region are close to being overloaded.</p>\n<p>German Health Minister Jens Spahn said that although the risk of blood clots was low, it could not be ruled out.</p>\n<p>“This is a professional decision, not a political one,” Spahn said, adding he was following a recommendation of the Paul Ehrlich Institute, Germany’s vaccine regulator.</p>\n<p>France said it was suspending the vaccine’s use pending an assessment by EMA.</p>\n<p>“The decision taken, in conformity also with our European policy, is to suspend, out of precaution, vaccination with the AZ shot, hoping that we can resume quickly if the EMA’s guidance allows,” French President Emmanuel Macron said.</p>\n<p>Italy said its halt was a “precautionary and temporary measure” pending EMA’s ruling.</p>\n<p>“The EMA will meet soon to clarify any doubts so that the AstraZeneca vaccine can be resumed safely in the vaccination campaign as soon as possible,” said Gianni Rezza, Director General of Prevention at Italy’s Ministry of Health.</p>\n<p>Austria and Spain have stopped using particular batches and prosecutors in the northern Italian region of Piedmont earlier seized 393,600 doses following the death of a man hours after he was vaccinated. It was the second region to do so after Sicily, where two people had died shortly after having their shots.</p>\n<p>The WHO appealed to countries not to suspend vaccinations against a disease that has caused more than 2.7 million deaths worldwide. WHO Director-General Tedros said systems were in place to protect public health.</p>\n<p>“This does not necessarily mean these events are linked to COVID-19 vaccination, but it’s routine practice to investigate them, and it shows that the surveillance system works and that effective controls are in place,” he told the media briefing.</p>\n<p>The United Kingdom said it had no concerns, while Poland said it thought the benefits outweighed any risks.</p>\n<p>The EMA has said that as of March 10, a total of 30 cases of blood clotting had been reported among close to 5 million people vaccinated with the AstraZeneca shot in the European Economic Area, which links 30 European countries.</p>\n<p>Michael Head, a senior research fellow in global health at the University of Southampton, said the decisions by France, Germany and others looked baffling.</p>\n<p>“The data we have suggests that numbers of adverse events related to blood clots are the same (and possibly, in fact lower) in vaccinated groups compared to unvaccinated populations,” he said, adding that halting a vaccination programme had consequences.</p>\n<p>“This results in delays in protecting people, and the potential for increased vaccine hesitancy, as a result of people who have seen the headlines and understandably become concerned. There are no signs yet of any data that really justify these decisions.”</p>\n<p>A senior German infectious diseases physician, however, said the background incidence of 2-5 thromboses per million per year was significantly lower than the number of 7 out of 1.6 million vaccinated people cited by Germany’s health ministry.</p>\n<p>“This should be the reason to suspend the vaccination in Germany until all cases, including suspected cases in Germany and Europe, have been completely cleared up,” said Clemens Wendtner, head of the special unit for highly contagious life threatening infections at the Schwabing Clinic in Munich.</p>\n<p><b>‘UNUSUAL’ SYMPTOMS</b></p>\n<p>AstraZeneca’s shot was among the first and cheapest to be developed and launched at volume since the coronavirus was first identified in central China at the end of 2019, and is set to be the mainstay of vaccination programmes in much of the developing world.</p>\n<p>Thailand announced plans on Monday to go ahead with the Anglo-Swedish firm’s shot after suspending its use on Friday, but Indonesia said it would wait for the WHO to report.</p>\n<p>The WHO said its advisory panel was reviewing reports related to the shot and would release its findings as soon as possible. But it said it was unlikely to change its recommendations, issued last month, for widespread use, including in countries where the South African variant of the virus may reduce its efficacy.</p>\n<p>The EMA has also said there was no indication the events were caused by the vaccination and that the number of reported blood clots was no higher than seen in the general population.</p>\n<p>But the handful of reported side-effects in Europe have upset vaccination programmes already stumbling over slow rollouts and vaccine scepticism in some countries.</p>\n<p>The Netherlands said on Monday it had seen 10 cases of possible noteworthy adverse side-effects from the AstraZeneca shot, hours after putting its vaccination programme on hold following reports of potential side-effects in other countries.</p>\n<p>Recent information indicates “a very special, rarely occurring form of thrombosis, of which some cases appear to have occurred shortly after vaccination. This is of course suspicious and should be investigated,” said Anke Huckriede, vaccinology professor at the University of Groningen in the Netherlands.</p>\n<p>Denmark reported “highly unusual” symptoms in a 60-year-old citizen who died from a blood clot after receiving the vaccine, the same phrase used on Saturday by Norway about three people under the age of 50 it said were being treated in hospital.</p>\n<p>One of the three health workers hospitalised in Norway after receiving the AstraZeneca shot had died, health authorities said on Monday, but there was no evidence the vaccine was the cause.</p>\n<p>AstraZeneca said earlier it had conducted a review covering more than 17 million people vaccinated in the EU and the UK which had shown no evidence of an increased risk of blood clots.</p>\n<p>Long-awaited results from AstraZeneca’s 30,000-person U.S. vaccine trial are now being reviewed by independent monitors to determine whether the shot is safe and effective, a top U.S. official said on Monday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Germany, Italy, France suspend AstraZeneca shots amid safety fears, disrupting EU vaccinations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGermany, Italy, France suspend AstraZeneca shots amid safety fears, disrupting EU vaccinations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-16 05:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Germany, France and Italy said on Monday they would suspend AstraZeneca COVID-19 shots after several countries reported possible serious side-effects, but the World Health Organization&nbsp;(WHO) said there was no proven link and people should not panic.</p>\n<p>Still, the decision by the European Union’s three biggest countries to put inoculations with the AstraZeneca shot on hold threw the already struggling vaccination campaign in the 27-nation EU into disarray.</p>\n<p>Denmark and Norway stopped giving the shot last week after reporting isolated cases of bleeding, blood clots and a low platelet count. Iceland and Bulgaria followed suit and Ireland and the Netherlands announced suspensions on Sunday.</p>\n<p>Spain will stop using the vaccine for at least 15 days, Cadena Ser radio reported, citing unnamed sources.</p>\n<p>The top WHO scientist reiterated on Monday that there have been no documented deaths linked to COVID-19 vaccines.</p>\n<p>“We do not want people to panic,” Soumya Swaminathan said on a virtual media briefing, adding there has been no association, so far, pinpointed between so-called “thromboembolic events” reported in some countries and COVID-19 shots.</p>\n<p>WHO chief Tedros Adhanom Ghebreyesus said an advisory committee meeting on AstraZeneca would be held on Tuesday. EU medicines regulator EMA will also convene this week to assess the information gathered into whether the AstraZeneca shot contributed to thromboembolic events in those inoculated.</p>\n<p>The moves by some of Europe’s largest and most populous countries will deepen concerns about the slow rollout of vaccines in the region, which has been plagued by shortages due to problems producing vaccines, including AstraZeneca’s.</p>\n<p>Germany warned last week it was facing a third wave of infections, Italy is intensifying lockdowns and hospitals in the Paris region are close to being overloaded.</p>\n<p>German Health Minister Jens Spahn said that although the risk of blood clots was low, it could not be ruled out.</p>\n<p>“This is a professional decision, not a political one,” Spahn said, adding he was following a recommendation of the Paul Ehrlich Institute, Germany’s vaccine regulator.</p>\n<p>France said it was suspending the vaccine’s use pending an assessment by EMA.</p>\n<p>“The decision taken, in conformity also with our European policy, is to suspend, out of precaution, vaccination with the AZ shot, hoping that we can resume quickly if the EMA’s guidance allows,” French President Emmanuel Macron said.</p>\n<p>Italy said its halt was a “precautionary and temporary measure” pending EMA’s ruling.</p>\n<p>“The EMA will meet soon to clarify any doubts so that the AstraZeneca vaccine can be resumed safely in the vaccination campaign as soon as possible,” said Gianni Rezza, Director General of Prevention at Italy’s Ministry of Health.</p>\n<p>Austria and Spain have stopped using particular batches and prosecutors in the northern Italian region of Piedmont earlier seized 393,600 doses following the death of a man hours after he was vaccinated. It was the second region to do so after Sicily, where two people had died shortly after having their shots.</p>\n<p>The WHO appealed to countries not to suspend vaccinations against a disease that has caused more than 2.7 million deaths worldwide. WHO Director-General Tedros said systems were in place to protect public health.</p>\n<p>“This does not necessarily mean these events are linked to COVID-19 vaccination, but it’s routine practice to investigate them, and it shows that the surveillance system works and that effective controls are in place,” he told the media briefing.</p>\n<p>The United Kingdom said it had no concerns, while Poland said it thought the benefits outweighed any risks.</p>\n<p>The EMA has said that as of March 10, a total of 30 cases of blood clotting had been reported among close to 5 million people vaccinated with the AstraZeneca shot in the European Economic Area, which links 30 European countries.</p>\n<p>Michael Head, a senior research fellow in global health at the University of Southampton, said the decisions by France, Germany and others looked baffling.</p>\n<p>“The data we have suggests that numbers of adverse events related to blood clots are the same (and possibly, in fact lower) in vaccinated groups compared to unvaccinated populations,” he said, adding that halting a vaccination programme had consequences.</p>\n<p>“This results in delays in protecting people, and the potential for increased vaccine hesitancy, as a result of people who have seen the headlines and understandably become concerned. There are no signs yet of any data that really justify these decisions.”</p>\n<p>A senior German infectious diseases physician, however, said the background incidence of 2-5 thromboses per million per year was significantly lower than the number of 7 out of 1.6 million vaccinated people cited by Germany’s health ministry.</p>\n<p>“This should be the reason to suspend the vaccination in Germany until all cases, including suspected cases in Germany and Europe, have been completely cleared up,” said Clemens Wendtner, head of the special unit for highly contagious life threatening infections at the Schwabing Clinic in Munich.</p>\n<p><b>‘UNUSUAL’ SYMPTOMS</b></p>\n<p>AstraZeneca’s shot was among the first and cheapest to be developed and launched at volume since the coronavirus was first identified in central China at the end of 2019, and is set to be the mainstay of vaccination programmes in much of the developing world.</p>\n<p>Thailand announced plans on Monday to go ahead with the Anglo-Swedish firm’s shot after suspending its use on Friday, but Indonesia said it would wait for the WHO to report.</p>\n<p>The WHO said its advisory panel was reviewing reports related to the shot and would release its findings as soon as possible. But it said it was unlikely to change its recommendations, issued last month, for widespread use, including in countries where the South African variant of the virus may reduce its efficacy.</p>\n<p>The EMA has also said there was no indication the events were caused by the vaccination and that the number of reported blood clots was no higher than seen in the general population.</p>\n<p>But the handful of reported side-effects in Europe have upset vaccination programmes already stumbling over slow rollouts and vaccine scepticism in some countries.</p>\n<p>The Netherlands said on Monday it had seen 10 cases of possible noteworthy adverse side-effects from the AstraZeneca shot, hours after putting its vaccination programme on hold following reports of potential side-effects in other countries.</p>\n<p>Recent information indicates “a very special, rarely occurring form of thrombosis, of which some cases appear to have occurred shortly after vaccination. This is of course suspicious and should be investigated,” said Anke Huckriede, vaccinology professor at the University of Groningen in the Netherlands.</p>\n<p>Denmark reported “highly unusual” symptoms in a 60-year-old citizen who died from a blood clot after receiving the vaccine, the same phrase used on Saturday by Norway about three people under the age of 50 it said were being treated in hospital.</p>\n<p>One of the three health workers hospitalised in Norway after receiving the AstraZeneca shot had died, health authorities said on Monday, but there was no evidence the vaccine was the cause.</p>\n<p>AstraZeneca said earlier it had conducted a review covering more than 17 million people vaccinated in the EU and the UK which had shown no evidence of an increased risk of blood clots.</p>\n<p>Long-awaited results from AstraZeneca’s 30,000-person U.S. vaccine trial are now being reviewed by independent monitors to determine whether the shot is safe and effective, a top U.S. official said on Monday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145894014","content_text":"Germany, France and Italy said on Monday they would suspend AstraZeneca COVID-19 shots after several countries reported possible serious side-effects, but the World Health Organization (WHO) said there was no proven link and people should not panic.\nStill, the decision by the European Union’s three biggest countries to put inoculations with the AstraZeneca shot on hold threw the already struggling vaccination campaign in the 27-nation EU into disarray.\nDenmark and Norway stopped giving the shot last week after reporting isolated cases of bleeding, blood clots and a low platelet count. Iceland and Bulgaria followed suit and Ireland and the Netherlands announced suspensions on Sunday.\nSpain will stop using the vaccine for at least 15 days, Cadena Ser radio reported, citing unnamed sources.\nThe top WHO scientist reiterated on Monday that there have been no documented deaths linked to COVID-19 vaccines.\n“We do not want people to panic,” Soumya Swaminathan said on a virtual media briefing, adding there has been no association, so far, pinpointed between so-called “thromboembolic events” reported in some countries and COVID-19 shots.\nWHO chief Tedros Adhanom Ghebreyesus said an advisory committee meeting on AstraZeneca would be held on Tuesday. EU medicines regulator EMA will also convene this week to assess the information gathered into whether the AstraZeneca shot contributed to thromboembolic events in those inoculated.\nThe moves by some of Europe’s largest and most populous countries will deepen concerns about the slow rollout of vaccines in the region, which has been plagued by shortages due to problems producing vaccines, including AstraZeneca’s.\nGermany warned last week it was facing a third wave of infections, Italy is intensifying lockdowns and hospitals in the Paris region are close to being overloaded.\nGerman Health Minister Jens Spahn said that although the risk of blood clots was low, it could not be ruled out.\n“This is a professional decision, not a political one,” Spahn said, adding he was following a recommendation of the Paul Ehrlich Institute, Germany’s vaccine regulator.\nFrance said it was suspending the vaccine’s use pending an assessment by EMA.\n“The decision taken, in conformity also with our European policy, is to suspend, out of precaution, vaccination with the AZ shot, hoping that we can resume quickly if the EMA’s guidance allows,” French President Emmanuel Macron said.\nItaly said its halt was a “precautionary and temporary measure” pending EMA’s ruling.\n“The EMA will meet soon to clarify any doubts so that the AstraZeneca vaccine can be resumed safely in the vaccination campaign as soon as possible,” said Gianni Rezza, Director General of Prevention at Italy’s Ministry of Health.\nAustria and Spain have stopped using particular batches and prosecutors in the northern Italian region of Piedmont earlier seized 393,600 doses following the death of a man hours after he was vaccinated. It was the second region to do so after Sicily, where two people had died shortly after having their shots.\nThe WHO appealed to countries not to suspend vaccinations against a disease that has caused more than 2.7 million deaths worldwide. WHO Director-General Tedros said systems were in place to protect public health.\n“This does not necessarily mean these events are linked to COVID-19 vaccination, but it’s routine practice to investigate them, and it shows that the surveillance system works and that effective controls are in place,” he told the media briefing.\nThe United Kingdom said it had no concerns, while Poland said it thought the benefits outweighed any risks.\nThe EMA has said that as of March 10, a total of 30 cases of blood clotting had been reported among close to 5 million people vaccinated with the AstraZeneca shot in the European Economic Area, which links 30 European countries.\nMichael Head, a senior research fellow in global health at the University of Southampton, said the decisions by France, Germany and others looked baffling.\n“The data we have suggests that numbers of adverse events related to blood clots are the same (and possibly, in fact lower) in vaccinated groups compared to unvaccinated populations,” he said, adding that halting a vaccination programme had consequences.\n“This results in delays in protecting people, and the potential for increased vaccine hesitancy, as a result of people who have seen the headlines and understandably become concerned. There are no signs yet of any data that really justify these decisions.”\nA senior German infectious diseases physician, however, said the background incidence of 2-5 thromboses per million per year was significantly lower than the number of 7 out of 1.6 million vaccinated people cited by Germany’s health ministry.\n“This should be the reason to suspend the vaccination in Germany until all cases, including suspected cases in Germany and Europe, have been completely cleared up,” said Clemens Wendtner, head of the special unit for highly contagious life threatening infections at the Schwabing Clinic in Munich.\n‘UNUSUAL’ SYMPTOMS\nAstraZeneca’s shot was among the first and cheapest to be developed and launched at volume since the coronavirus was first identified in central China at the end of 2019, and is set to be the mainstay of vaccination programmes in much of the developing world.\nThailand announced plans on Monday to go ahead with the Anglo-Swedish firm’s shot after suspending its use on Friday, but Indonesia said it would wait for the WHO to report.\nThe WHO said its advisory panel was reviewing reports related to the shot and would release its findings as soon as possible. But it said it was unlikely to change its recommendations, issued last month, for widespread use, including in countries where the South African variant of the virus may reduce its efficacy.\nThe EMA has also said there was no indication the events were caused by the vaccination and that the number of reported blood clots was no higher than seen in the general population.\nBut the handful of reported side-effects in Europe have upset vaccination programmes already stumbling over slow rollouts and vaccine scepticism in some countries.\nThe Netherlands said on Monday it had seen 10 cases of possible noteworthy adverse side-effects from the AstraZeneca shot, hours after putting its vaccination programme on hold following reports of potential side-effects in other countries.\nRecent information indicates “a very special, rarely occurring form of thrombosis, of which some cases appear to have occurred shortly after vaccination. This is of course suspicious and should be investigated,” said Anke Huckriede, vaccinology professor at the University of Groningen in the Netherlands.\nDenmark reported “highly unusual” symptoms in a 60-year-old citizen who died from a blood clot after receiving the vaccine, the same phrase used on Saturday by Norway about three people under the age of 50 it said were being treated in hospital.\nOne of the three health workers hospitalised in Norway after receiving the AstraZeneca shot had died, health authorities said on Monday, but there was no evidence the vaccine was the cause.\nAstraZeneca said earlier it had conducted a review covering more than 17 million people vaccinated in the EU and the UK which had shown no evidence of an increased risk of blood clots.\nLong-awaited results from AstraZeneca’s 30,000-person U.S. vaccine trial are now being reviewed by independent monitors to determine whether the shot is safe and effective, a top U.S. official said on Monday.","news_type":1,"symbols_score_info":{"AZN.UK":0.9,"AZN":0.9}},"isVote":1,"tweetType":1,"viewCount":1672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322670070,"gmtCreate":1615806244890,"gmtModify":1704786767884,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"Appreciate posts like this that end up on Tiger’s news page. It helps us do due diligence easily&nbsp;","listText":"Appreciate posts like this that end up on Tiger’s news page. It helps us do due diligence easily&nbsp;","text":"Appreciate posts like this that end up on Tiger’s news page. It helps us do due diligence easily","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322670070","repostId":"1164885443","repostType":4,"repost":{"id":"1164885443","kind":"news","pubTimestamp":1615805768,"share":"https://ttm.financial/m/news/1164885443?lang=en_US&edition=fundamental","pubTime":"2021-03-15 18:56","market":"us","language":"en","title":"10 Stocks That Are Vulnerable to a Blowup","url":"https://stock-news.laohu8.com/highlight/detail?id=1164885443","media":"Barrons","summary":"Avoiding stock blowups is in every investor’s interest, but it’s getting a bit tougher.Many companie","content":"<p>Avoiding stock blowups is in every investor’s interest, but it’s getting a bit tougher.</p><p>Many companies that beat fourth-quarter estimates haven’t been rewarded with higher share prices. High-growth stocks are facing steeper hurdles from rising bond yields. Investors appear to be rotating from growth to value and into sectors with more exposure to a cyclical economic recovery.</p><p>Quite simply, fatigue may be setting into overcrowded trades and investment themes—whether those are alternative-meat producers, a travel recovery, green energy, or the continued domination of Big Tech.</p><p>Against that backdrop, investors may want to tread cautiously. One way to do so: Avoid stocks with low earnings quality and high short interest—meaning there are short positions, or bearish bets, on a large percentage of a company’s shares outstanding. (A short position is when investors borrow and then sell shares, betting that a stock’s price will fall so they can buy shares back at a cheaper price.) Stocks with that combination of attributes may be most at risk of underperforming or blowing up, according to Wolfe Research.</p><p>The firm ranks stocks on a relative basis within sectors by scoring earnings quality on seven financial measures, while also looking at valuation and sentiment indicators, based on fourth-quarter financials.</p><p>Wolfe calls stocks scoring in the bottom 10% of earnings quality, while also seeing high short interest, “our highest conviction cohort of stocks to avoid.”</p><p>One caveat: Low-quality stocks have been a popular trade—fueled by ample market liquidity and demand for riskier assets. High short interest also primes a stock for a short-squeeze, whereby traders who are short buy the stock to cover their positions, exerting upward pressure on the price. Nothing illustrates that dynamic more than the frenzied trading around GameStop (ticker: GME) this year.</p><p>Beauty products maker Coty (COTY), for example, shows up on Wolfe’s screen. But it may have already had its blowup, falling 15% the day it released its earnings report in February. Barron’s was bullish on the stock in the aftermath, and it has been moving up since then.</p><p>Nonetheless, plenty of other stocks on Wolfe’s watch list do seem vulnerable. Many have surged in a reopening trade or company-specific dynamics, and all trade at steep valuations. Here are 10 stocks from Wolfe’s list:</p><p>Carvana (CVNA), for instance, has been a blockbuster, gaining 535% over the last 52 weeks. Investors appear to have decided that it is a disruptive force in car buying and that a pandemic-fueled shift to online sales has accelerated its momentum. However, Carvana isn’t close to reporting a profit, and is expected to lose $1.96 a share this year and 97 cents in 2022.</p><p>The stock is up around 11% this year, but it has been wobbling lately and is down from its 52-week high around $315, trading recently at $287. Short interest is high at 22% of the shares outstanding, according to FactSet.</p><p>Expedia Group (EXPE) has surged 32% this year. Investors expect online bookings volume to soar as consumers head for vacations this summer and fall. Wall Street doesn’t see Expedia Group earning a profit this year but expects big gains in 2022 with earnings per share of $6.04. At recent prices around $175, shares trade at 28 times 2022 earnings, a 40% premium to the S&amp;P 500 ‘s multiple of 20 times.</p><p>Norwegian Cruise Line Holdings (NCLH) is also trading on hopes for a travel rebound in 2022. Wall Street expects revenues of $1.6 billion this year, up from $1.3 billion in 2020. But the stock is riding on expectations of a surge to $6 billion in revenue in 2022. Analysts are looking for earnings of 62 cents a share in 2022, up from an expected loss of $5.87 a share this year. The stock has climbed 218% in the last 52 weeks, and it is powering ahead this year, up 21% so far.</p><p>It’s hardly cheap, though, at 50 times estimated 2022 profits. About 13% of the shares are held short, according to FactSet.</p><p>Lyft (LYFT) also fits into the reopening theme; shares are up 178% in the last 52 weeks, including a 35% gain this year. Ride-sharing could pick up as more people head to work, meetings, and evenings out.</p><p>However, Lyft and its chief rival Uber Technologies (UBER) face rising labor costs and regulatory hurdles in Europe and other regions. Wall Street sees Lyft losing $1.08 a share this year and turning a modest profit of 17 cents in 2022. That gives it a multiple of 379 times 2022 earnings. Short interest is around 9%.</p><p>Restoration Hardware parent Restoration Hardware (RH) has been a stay-at-home winner. The stock soared 338% over the last year and it’s ahead 5% this year. The company is profitable, expected to earn $19.17 a share this year, up from an estimated $17.05 in 2020. But the stock hit a rough patch in early March as high-growth, high-multiple stocks sold off.</p><p>RH trades at 22 times 2022 earnings, which doesn’t look excessive. But It is now vulnerable to a blowup, according to Wolfe, with short-interest at 11% of the float.</p><p>Beyond Meat (BYND) has long been a battleground between alt-meat bulls and bears. The stock has surged 93% over the last 52 weeks, defying the bears, but at recent prices around $142, it’s off 36% from its 52-week high of $221.</p><p>The alt-meat trend is going strong, and Beyond is working its way into more restaurants and supermarkets, while expanding its product line. But alt-meat rivals are gaining traction. Beyond’s profits aren’t expected to roll in until 2022, when the firm is anticipated to earn 23 cents a share. At that level of profit, the stock trades at 621 times earnings.</p><p>Stocks like Beyond trade on underlying business momentum, making earnings less of a share-price driver. Still, it isn’t encouraging that Wall Street sees the losses piling up. Per-share estimates for 2021 have been lowered 12% in the last week, according to FactSet, and 2021 estimates are down 190% in the past three months.</p><p>Meanwhile, First Solar (FSLR) is riding a wave of investor demand for green stocks from ESG funds and others looking for exposure to clean energy. The company, which makes solar power systems and modules, has gained 124% over the last 52 weeks. The company has reported strong sales and bookings, but the stock is also baking in friendly climate policies from the Biden administration.</p><p>The stock has been wavering, however, after its big run. It has slumped 17% this year and it’s off more than 20% from 52-week highs around $112, recently trading around $82. Despite a favorable backdrop for green energy, First Solar’s sales and earnings are expected to fall slightly from 2021 to 2022. The stock trades at 24 times 2022 earnings, a premium to the market.</p><p>Other large-cap stocks that make Wolfe’s blowup watch list include BioMarin Pharmaceutical (BMRN), Zendesk (ZEN), and Advanced Micro Devices (AMD). Zendesk and AMD are each up more than 100% over the last year, while BioMarin has been flat. All trade at steep valuations, with Zendesk topping the list at 130 times 2022 earnings estimates.</p><p>A blowup may not be imminent in any of these names, but stocks without a significant profit in sight may fall sharply if market jitters resurface and investors start to appreciate higher earnings quality.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Stocks That Are Vulnerable to a Blowup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Stocks That Are Vulnerable to a Blowup\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 18:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/beyond-meat-stock-expedia-lyft-vulnerable-blowup-51615588807?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Avoiding stock blowups is in every investor’s interest, but it’s getting a bit tougher.Many companies that beat fourth-quarter estimates haven’t been rewarded with higher share prices. High-growth ...</p>\n\n<a href=\"https://www.barrons.com/articles/beyond-meat-stock-expedia-lyft-vulnerable-blowup-51615588807?mod=hp_LATEST\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXPE":"Expedia","COTY":"科蒂","CVNA":"Carvana Co.","BYND":"Beyond Meat, Inc.","BMRN":"拜玛林制药","FSLR":"第一太阳能","AMD":"美国超微公司","LYFT":"Lyft, Inc.","NCLH":"挪威邮轮","RH":"RH"},"source_url":"https://www.barrons.com/articles/beyond-meat-stock-expedia-lyft-vulnerable-blowup-51615588807?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164885443","content_text":"Avoiding stock blowups is in every investor’s interest, but it’s getting a bit tougher.Many companies that beat fourth-quarter estimates haven’t been rewarded with higher share prices. High-growth stocks are facing steeper hurdles from rising bond yields. Investors appear to be rotating from growth to value and into sectors with more exposure to a cyclical economic recovery.Quite simply, fatigue may be setting into overcrowded trades and investment themes—whether those are alternative-meat producers, a travel recovery, green energy, or the continued domination of Big Tech.Against that backdrop, investors may want to tread cautiously. One way to do so: Avoid stocks with low earnings quality and high short interest—meaning there are short positions, or bearish bets, on a large percentage of a company’s shares outstanding. (A short position is when investors borrow and then sell shares, betting that a stock’s price will fall so they can buy shares back at a cheaper price.) Stocks with that combination of attributes may be most at risk of underperforming or blowing up, according to Wolfe Research.The firm ranks stocks on a relative basis within sectors by scoring earnings quality on seven financial measures, while also looking at valuation and sentiment indicators, based on fourth-quarter financials.Wolfe calls stocks scoring in the bottom 10% of earnings quality, while also seeing high short interest, “our highest conviction cohort of stocks to avoid.”One caveat: Low-quality stocks have been a popular trade—fueled by ample market liquidity and demand for riskier assets. High short interest also primes a stock for a short-squeeze, whereby traders who are short buy the stock to cover their positions, exerting upward pressure on the price. Nothing illustrates that dynamic more than the frenzied trading around GameStop (ticker: GME) this year.Beauty products maker Coty (COTY), for example, shows up on Wolfe’s screen. But it may have already had its blowup, falling 15% the day it released its earnings report in February. Barron’s was bullish on the stock in the aftermath, and it has been moving up since then.Nonetheless, plenty of other stocks on Wolfe’s watch list do seem vulnerable. Many have surged in a reopening trade or company-specific dynamics, and all trade at steep valuations. Here are 10 stocks from Wolfe’s list:Carvana (CVNA), for instance, has been a blockbuster, gaining 535% over the last 52 weeks. Investors appear to have decided that it is a disruptive force in car buying and that a pandemic-fueled shift to online sales has accelerated its momentum. However, Carvana isn’t close to reporting a profit, and is expected to lose $1.96 a share this year and 97 cents in 2022.The stock is up around 11% this year, but it has been wobbling lately and is down from its 52-week high around $315, trading recently at $287. Short interest is high at 22% of the shares outstanding, according to FactSet.Expedia Group (EXPE) has surged 32% this year. Investors expect online bookings volume to soar as consumers head for vacations this summer and fall. Wall Street doesn’t see Expedia Group earning a profit this year but expects big gains in 2022 with earnings per share of $6.04. At recent prices around $175, shares trade at 28 times 2022 earnings, a 40% premium to the S&P 500 ‘s multiple of 20 times.Norwegian Cruise Line Holdings (NCLH) is also trading on hopes for a travel rebound in 2022. Wall Street expects revenues of $1.6 billion this year, up from $1.3 billion in 2020. But the stock is riding on expectations of a surge to $6 billion in revenue in 2022. Analysts are looking for earnings of 62 cents a share in 2022, up from an expected loss of $5.87 a share this year. The stock has climbed 218% in the last 52 weeks, and it is powering ahead this year, up 21% so far.It’s hardly cheap, though, at 50 times estimated 2022 profits. About 13% of the shares are held short, according to FactSet.Lyft (LYFT) also fits into the reopening theme; shares are up 178% in the last 52 weeks, including a 35% gain this year. Ride-sharing could pick up as more people head to work, meetings, and evenings out.However, Lyft and its chief rival Uber Technologies (UBER) face rising labor costs and regulatory hurdles in Europe and other regions. Wall Street sees Lyft losing $1.08 a share this year and turning a modest profit of 17 cents in 2022. That gives it a multiple of 379 times 2022 earnings. Short interest is around 9%.Restoration Hardware parent Restoration Hardware (RH) has been a stay-at-home winner. The stock soared 338% over the last year and it’s ahead 5% this year. The company is profitable, expected to earn $19.17 a share this year, up from an estimated $17.05 in 2020. But the stock hit a rough patch in early March as high-growth, high-multiple stocks sold off.RH trades at 22 times 2022 earnings, which doesn’t look excessive. But It is now vulnerable to a blowup, according to Wolfe, with short-interest at 11% of the float.Beyond Meat (BYND) has long been a battleground between alt-meat bulls and bears. The stock has surged 93% over the last 52 weeks, defying the bears, but at recent prices around $142, it’s off 36% from its 52-week high of $221.The alt-meat trend is going strong, and Beyond is working its way into more restaurants and supermarkets, while expanding its product line. But alt-meat rivals are gaining traction. Beyond’s profits aren’t expected to roll in until 2022, when the firm is anticipated to earn 23 cents a share. At that level of profit, the stock trades at 621 times earnings.Stocks like Beyond trade on underlying business momentum, making earnings less of a share-price driver. Still, it isn’t encouraging that Wall Street sees the losses piling up. Per-share estimates for 2021 have been lowered 12% in the last week, according to FactSet, and 2021 estimates are down 190% in the past three months.Meanwhile, First Solar (FSLR) is riding a wave of investor demand for green stocks from ESG funds and others looking for exposure to clean energy. The company, which makes solar power systems and modules, has gained 124% over the last 52 weeks. The company has reported strong sales and bookings, but the stock is also baking in friendly climate policies from the Biden administration.The stock has been wavering, however, after its big run. It has slumped 17% this year and it’s off more than 20% from 52-week highs around $112, recently trading around $82. Despite a favorable backdrop for green energy, First Solar’s sales and earnings are expected to fall slightly from 2021 to 2022. The stock trades at 24 times 2022 earnings, a premium to the market.Other large-cap stocks that make Wolfe’s blowup watch list include BioMarin Pharmaceutical (BMRN), Zendesk (ZEN), and Advanced Micro Devices (AMD). Zendesk and AMD are each up more than 100% over the last year, while BioMarin has been flat. All trade at steep valuations, with Zendesk topping the list at 130 times 2022 earnings estimates.A blowup may not be imminent in any of these names, but stocks without a significant profit in sight may fall sharply if market jitters resurface and investors start to appreciate higher earnings quality.","news_type":1,"symbols_score_info":{"CVNA":0.9,"FSLR":0.9,"ZEN":0.9,"RH":0.9,"AMD":0.9,"LYFT":0.9,"BYND":0.9,"NCLH":0.9,"BMRN":0.9,"EXPE":0.9,"COTY":0.9}},"isVote":1,"tweetType":1,"viewCount":1491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322982142,"gmtCreate":1615767483186,"gmtModify":1704786162668,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"Indeed this will be interesting to watch!","listText":"Indeed this will be interesting to watch!","text":"Indeed this will be interesting to watch!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322982142","repostId":"1155155337","repostType":4,"repost":{"id":"1155155337","kind":"news","pubTimestamp":1615765765,"share":"https://ttm.financial/m/news/1155155337?lang=en_US&edition=fundamental","pubTime":"2021-03-15 07:49","market":"us","language":"en","title":"Pinduoduo, Nike,AMD, Lennar, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1155155337","media":"Barrons","summary":"The earnings calendar is sparse this week. The few major companies reporting include home-builder Le","content":"<p>The earnings calendar is sparse this week. The few major companies reporting include home-builder&nbsp;Lennaron Tuesday and Pinduoduo,business-services firm&nbsp;Cintason Wednesday. Thursday will be more interesting as&nbsp;Nike,FedEx,and&nbsp;Dollar General&nbsp;report.Advanced Micro Deviceswill also host an event on Monday to unveil new chips.</p><p>The economic calendar this week will be more eventful. The Federal Reserve’s monetary policy committee’s March meeting concludes on Wednesday, with its latest decision&nbsp;and a press conference from chairman Jerome Powell coming that afternoon. TheBank of Japanwill announce its latest policy move on Friday.</p><p>Economic data out this week includes the Census Bureau’s retail-sales data for February on Tuesday, along with the National Association of Home Builders’ NAHB/Wells FargoHousing Market index for March. Then on Wednesday, the Census Bureau reports residential construction data for February. And on Thursday, the Conference Board releases its Leading Economic index for February.</p><p><b>Monday 3/15</b></p><p>Advanced Micro Devices hosts a conference call in conjunction with the launch of its third-generation EPYC processors. Senior management, including CEO Lisa Su, will give presentations on the new chips. AMD shares doubled last year, making them the 10th best performers in the&nbsp;S&amp;P 500.</p><p><b>The Federal Reserve</b>&nbsp;Bank of New York releases its Empire State Manufacturing Survey for March. The consensus estimate is for a 16.5 reading, versus February’s 12.1. The index has had eight consecutive months of positive readings, indicating improving conditions in the region’s manufacturing sector.</p><p><b>Tuesday 3/16</b></p><p><b>CrowdStrike Holdings</b>&nbsp;and Lennar report quarterly results.</p><p><b>The National Association</b>&nbsp;of Home Builders releases its NAHB/Wells Fargo Housing Market index for March. Economists forecast an 84 reading, even with February’s. The index is off its all-time high of 90, set last November, but home builders remain bullish on the housing market.</p><p><b>The Census Bureau</b>&nbsp;reports retail-sales data for February. Expectations are for a 0.7% month-over-month decline, after a 5.3% jump in January. Excluding autos, spending is seen edging down 0.1%, compared with a 5.9% increase previously.</p><p><b>Wednesday 3/17</b></p><p><b>The Federal Open Market Committee</b>announces its monetary-policy decision. The Federal Reserve has stressed that it will keep interest rates near zero through 2023, but might tweak its bond-buying program.</p><p><b>Cintas and Five Below</b>&nbsp;report earnings.</p><p><b>Pinduoduo</b>&nbsp;report earnings.</p><p><b>The Census Bureau</b>&nbsp;reports residential construction data for February. The consensus call is for a seasonally adjusted annual rate of 1.57 million housing starts, in line with the January figure. Housing starts remain just off their post-financial-crisis peak.</p><p><b>Thursday 3/18</b></p><p>Accenture,Dollar General, FedEx, and Nike hold conference calls to discuss quarterly results.</p><p><b>The Conference Board</b>&nbsp;releases its Leading Economic index for February. Economists forecast a 0.4% monthly rise. The LEI has increased every month since last April, though the rate of growth has slowed since the third quarter of last year.</p><p><b>The Department of Labor</b>&nbsp;reports jobless claims for the week ended on March 13. This past week’s total of 712,000claims was the second lowest since the beginning of the Covid-19 pandemic.</p><p><b>Friday 3/19</b></p><p><b>The Bank of Japan</b>&nbsp;announces its monetary-policy decision after a two-day meeting. The central bank is widely expected to keep its key short-term interest rate unchanged, at a negative 0.1%. The BOJ also will review its policy tools during the meeting.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pinduoduo, Nike,AMD, Lennar, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPinduoduo, Nike,AMD, Lennar, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 07:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/nike-fedex-amd-lennar-and-other-stocks-for-investors-to-watch-this-week-51615748409?mod=hp_LEAD_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The earnings calendar is sparse this week. The few major companies reporting include home-builder Lennaron Tuesday and Pinduoduo,business-services firm Cintason Wednesday. Thursday will be more ...</p>\n\n<a href=\"https://www.barrons.com/articles/nike-fedex-amd-lennar-and-other-stocks-for-investors-to-watch-this-week-51615748409?mod=hp_LEAD_2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FDX":"联邦快递","PDD":"拼多多","NKE":"耐克","AMD":"美国超微公司"},"source_url":"https://www.barrons.com/articles/nike-fedex-amd-lennar-and-other-stocks-for-investors-to-watch-this-week-51615748409?mod=hp_LEAD_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155155337","content_text":"The earnings calendar is sparse this week. The few major companies reporting include home-builder Lennaron Tuesday and Pinduoduo,business-services firm Cintason Wednesday. Thursday will be more interesting as Nike,FedEx,and Dollar General report.Advanced Micro Deviceswill also host an event on Monday to unveil new chips.The economic calendar this week will be more eventful. The Federal Reserve’s monetary policy committee’s March meeting concludes on Wednesday, with its latest decision and a press conference from chairman Jerome Powell coming that afternoon. TheBank of Japanwill announce its latest policy move on Friday.Economic data out this week includes the Census Bureau’s retail-sales data for February on Tuesday, along with the National Association of Home Builders’ NAHB/Wells FargoHousing Market index for March. Then on Wednesday, the Census Bureau reports residential construction data for February. And on Thursday, the Conference Board releases its Leading Economic index for February.Monday 3/15Advanced Micro Devices hosts a conference call in conjunction with the launch of its third-generation EPYC processors. Senior management, including CEO Lisa Su, will give presentations on the new chips. AMD shares doubled last year, making them the 10th best performers in the S&P 500.The Federal Reserve Bank of New York releases its Empire State Manufacturing Survey for March. The consensus estimate is for a 16.5 reading, versus February’s 12.1. The index has had eight consecutive months of positive readings, indicating improving conditions in the region’s manufacturing sector.Tuesday 3/16CrowdStrike Holdings and Lennar report quarterly results.The National Association of Home Builders releases its NAHB/Wells Fargo Housing Market index for March. Economists forecast an 84 reading, even with February’s. The index is off its all-time high of 90, set last November, but home builders remain bullish on the housing market.The Census Bureau reports retail-sales data for February. Expectations are for a 0.7% month-over-month decline, after a 5.3% jump in January. Excluding autos, spending is seen edging down 0.1%, compared with a 5.9% increase previously.Wednesday 3/17The Federal Open Market Committeeannounces its monetary-policy decision. The Federal Reserve has stressed that it will keep interest rates near zero through 2023, but might tweak its bond-buying program.Cintas and Five Below report earnings.Pinduoduo report earnings.The Census Bureau reports residential construction data for February. The consensus call is for a seasonally adjusted annual rate of 1.57 million housing starts, in line with the January figure. Housing starts remain just off their post-financial-crisis peak.Thursday 3/18Accenture,Dollar General, FedEx, and Nike hold conference calls to discuss quarterly results.The Conference Board releases its Leading Economic index for February. Economists forecast a 0.4% monthly rise. The LEI has increased every month since last April, though the rate of growth has slowed since the third quarter of last year.The Department of Labor reports jobless claims for the week ended on March 13. This past week’s total of 712,000claims was the second lowest since the beginning of the Covid-19 pandemic.Friday 3/19The Bank of Japan announces its monetary-policy decision after a two-day meeting. The central bank is widely expected to keep its key short-term interest rate unchanged, at a negative 0.1%. The BOJ also will review its policy tools during the meeting.","news_type":1,"symbols_score_info":{"NKE":0.9,"AMD":0.9,"PDD":0.9,"FDX":0.9}},"isVote":1,"tweetType":1,"viewCount":1387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328540228,"gmtCreate":1615543494764,"gmtModify":1704784342812,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"Yes indeed that is true","listText":"Yes indeed that is true","text":"Yes indeed that is true","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328540228","repostId":"1155506399","repostType":4,"isVote":1,"tweetType":1,"viewCount":1808,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":321669546,"gmtCreate":1615429632285,"gmtModify":1704782657766,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>Was a little disappointed that we didn’t hold the slope up yesterday but I guess it would be good to spend more time in consolidation mode. It could be difficult to see but will be healthier in the long run. Hoping for more sustained upside action in the months to come!","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>Was a little disappointed that we didn’t hold the slope up yesterday but I guess it would be good to spend more time in consolidation mode. It could be difficult to see but will be healthier in the long run. Hoping for more sustained upside action in the months to come!","text":"$Sea Ltd(SE)$Was a little disappointed that we didn’t hold the slope up yesterday but I guess it would be good to spend more time in consolidation mode. It could be difficult to see but will be healthier in the long run. Hoping for more sustained upside action in the months to come!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/321669546","isVote":1,"tweetType":1,"viewCount":1505,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323711472,"gmtCreate":1615374866296,"gmtModify":1704781844010,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AYRO\">$AYRO, Inc.(AYRO)$</a>Lol","listText":"<a href=\"https://laohu8.com/S/AYRO\">$AYRO, Inc.(AYRO)$</a>Lol","text":"$AYRO, Inc.(AYRO)$Lol","images":[{"img":"https://static.tigerbbs.com/5a7a068e1f845f68e0209af558d44d34","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/323711472","isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3571882312755933","authorId":"3571882312755933","name":"Alexngo","avatar":"https://community-static.tradeup.com/news/223e039a4ee6d691503ce2aee951d200","crmLevel":11,"crmLevelSwitch":1,"authorIdStr":"3571882312755933","idStr":"3571882312755933"},"content":"Did you average when the price dip last few days?","text":"Did you average when the price dip last few days?","html":"Did you average when the price dip last few days?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":323739872,"gmtCreate":1615373740896,"gmtModify":1704781827744,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"Must be careful","listText":"Must be careful","text":"Must be careful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/323739872","repostId":"2118269678","repostType":4,"repost":{"id":"2118269678","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1615370220,"share":"https://ttm.financial/m/news/2118269678?lang=en_US&edition=fundamental","pubTime":"2021-03-10 17:57","market":"hk","language":"en","title":"Investors blinded by over-optimism on vaccine rollout must see these risks, warns economist","url":"https://stock-news.laohu8.com/highlight/detail?id=2118269678","media":"Dow Jones","summary":"Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chines","content":"<blockquote>\n Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns this economist.\n</blockquote>\n<p>Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns a leading economist.</p>\n<p>Taimur Baig, chief economist at Singapore's DBS bank questions \"are we getting ahead of ourselves in beginning to look past the pandemic?\" Already, he notes, that bond yields have been firming \"in expectation of strong growth.\"</p>\n<p>He warns, in countries like the U.S., where vaccination pace has picked up, there will be a tendency among the population to let their guard down, and give up on wearing masks and social-distance requirements, causing a resurgence in infections.</p>\n<p>\"Outside of a few developed countries, the rate of vaccination is meager at the present stage\", he wrote in a Mar. 8 note. \"Vaccination-driven herd immunity is many months, if not years, away. Particularly worrisome is that with virus raging through the globe over the past year, a few potent variants have emerged.\"</p>\n<p>He says easing up on protective measures when variants are spreading could prove to be a huge mistake in the coming months, and says mask wearing and social distancing is absolutely critical.</p>\n<p>\"Otherwise, we are concerned that the SARS-Cov2 variants could end up making the market's normalization trades look highly premature,\" he warned.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors blinded by over-optimism on vaccine rollout must see these risks, warns economist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors blinded by over-optimism on vaccine rollout must see these risks, warns economist\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-03-10 17:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns this economist.\n</blockquote>\n<p>Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns a leading economist.</p>\n<p>Taimur Baig, chief economist at Singapore's DBS bank questions \"are we getting ahead of ourselves in beginning to look past the pandemic?\" Already, he notes, that bond yields have been firming \"in expectation of strong growth.\"</p>\n<p>He warns, in countries like the U.S., where vaccination pace has picked up, there will be a tendency among the population to let their guard down, and give up on wearing masks and social-distance requirements, causing a resurgence in infections.</p>\n<p>\"Outside of a few developed countries, the rate of vaccination is meager at the present stage\", he wrote in a Mar. 8 note. \"Vaccination-driven herd immunity is many months, if not years, away. Particularly worrisome is that with virus raging through the globe over the past year, a few potent variants have emerged.\"</p>\n<p>He says easing up on protective measures when variants are spreading could prove to be a huge mistake in the coming months, and says mask wearing and social distancing is absolutely critical.</p>\n<p>\"Otherwise, we are concerned that the SARS-Cov2 variants could end up making the market's normalization trades look highly premature,\" he warned.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2118269678","content_text":"Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns this economist.\n\nEnthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns a leading economist.\nTaimur Baig, chief economist at Singapore's DBS bank questions \"are we getting ahead of ourselves in beginning to look past the pandemic?\" Already, he notes, that bond yields have been firming \"in expectation of strong growth.\"\nHe warns, in countries like the U.S., where vaccination pace has picked up, there will be a tendency among the population to let their guard down, and give up on wearing masks and social-distance requirements, causing a resurgence in infections.\n\"Outside of a few developed countries, the rate of vaccination is meager at the present stage\", he wrote in a Mar. 8 note. \"Vaccination-driven herd immunity is many months, if not years, away. Particularly worrisome is that with virus raging through the globe over the past year, a few potent variants have emerged.\"\nHe says easing up on protective measures when variants are spreading could prove to be a huge mistake in the coming months, and says mask wearing and social distancing is absolutely critical.\n\"Otherwise, we are concerned that the SARS-Cov2 variants could end up making the market's normalization trades look highly premature,\" he warned.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323739389,"gmtCreate":1615373716141,"gmtModify":1704781828067,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"This is good news but I hope it sustains the bounce","listText":"This is good news but I hope it sustains the bounce","text":"This is good news but I hope it sustains the bounce","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323739389","repostId":"2117431698","repostType":2,"repost":{"id":"2117431698","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1615209330,"share":"https://ttm.financial/m/news/2117431698?lang=en_US&edition=fundamental","pubTime":"2021-03-08 21:15","market":"us","language":"en","title":"BRIEF-Ayro Inc - Launch Of Electric Vaccine Vehicle","url":"https://stock-news.laohu8.com/highlight/detail?id=2117431698","media":"Reuters","summary":"March 8 (Reuters) - AYRO Inc   :   * AYRO INC - LAUNCH OF ELECTRIC VACCINE VEHICLESource text for Ei","content":"<html><body><p>March 8 (Reuters) - AYRO Inc   :</p><p>   * AYRO INC - LAUNCH OF ELECTRIC VACCINE VEHICLE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ayro Inc - Launch Of Electric Vaccine Vehicle</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ayro Inc - Launch Of Electric Vaccine Vehicle\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-08 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>March 8 (Reuters) - AYRO Inc   :</p><p>   * AYRO INC - LAUNCH OF ELECTRIC VACCINE VEHICLE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","CGEM":"Cullinan Therapeutics","SANA":"Sana Biotechnology, Inc."},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117431698","content_text":"March 8 (Reuters) - AYRO Inc   :   * AYRO INC - LAUNCH OF ELECTRIC VACCINE VEHICLESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"SANA":1,"LABP":1,"APR":1,"LHDX":1,"CGEM":1,"AYRO":0.9}},"isVote":1,"tweetType":1,"viewCount":627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323596515,"gmtCreate":1615352128437,"gmtModify":1704781549665,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"It can bounce but I hope it maintains the bounce&nbsp;","listText":"It can bounce but I hope it maintains the bounce&nbsp;","text":"It can bounce but I hope it maintains the bounce","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323596515","repostId":"1140398434","repostType":4,"isVote":1,"tweetType":1,"viewCount":670,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323320685,"gmtCreate":1615303982947,"gmtModify":1704780943187,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>My only regret is not buying when Shopee launched in Singapore a few years ago. They’re actually doing quite well in terms of public sentiment and I think they’ll do well compared to direct competitors&nbsp;","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>My only regret is not buying when Shopee launched in Singapore a few years ago. They’re actually doing quite well in terms of public sentiment and I think they’ll do well compared to direct competitors&nbsp;","text":"$Sea Ltd(SE)$My only regret is not buying when Shopee launched in Singapore a few years ago. They’re actually doing quite well in terms of public sentiment and I think they’ll do well compared to direct competitors","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323320685","isVote":1,"tweetType":1,"viewCount":581,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323366601,"gmtCreate":1615303798003,"gmtModify":1704780934099,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"Go J&amp;J!","listText":"Go J&amp;J!","text":"Go J&J!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/323366601","repostId":"1117128744","repostType":4,"repost":{"id":"1117128744","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1615298116,"share":"https://ttm.financial/m/news/1117128744?lang=en_US&edition=fundamental","pubTime":"2021-03-09 21:55","market":"us","language":"en","title":"J&J 'under stress' to meet EU second-quarter vaccine supply goal - source","url":"https://stock-news.laohu8.com/highlight/detail?id=1117128744","media":"Reuters","summary":"Johnson & Johnson has told the European Union it is facing supply issues that may complicate plans t","content":"<p>Johnson &amp; Johnson has told the European Union it is facing supply issues that may complicate plans to deliver 55 million doses of its COVID-19 vaccine to the bloc in the second quarter of the year, an EU official told Reuters.</p><p>Any delay would be a further blow to EU’s vaccination plans, which have been hampered by bumpy supplies from other vaccine makers and a slow rollout of shots in many member states.</p><p>J&amp;J told the EU last week that issues with the supply of vaccine ingredients and equipment meant it was “under stress” to meet the goal of delivering 55 million doses by the end of June, the EU official - who is directly involved in confidential talks with the U.S. company - told Reuters on condition of anonymity.</p><p>The official added the company had said it was not impossible to meet the goal, but that it showed caution.</p><p>J&amp;J’s vaccine, which requires only one dose for protection, is expected to be approved on March 11 for use in the EU by the bloc’s regulator. EU officials have said deliveries could start in April.</p><p>The company has committed to deliver 200 million doses of its vaccine to the bloc this year.</p><p>“Aligned with our agreement, we expect to begin supplying our commitment of 200 million doses to the European Union in the second quarter of 2021,” J&amp;J said in a statement, declining to comment on possible delays or the second-quarter target.</p><p>J&amp;J began rolling out its vaccine in the United States this month, with a target of delivering 100 million doses by the end of May, but has nearly halved its delivery forecasts for March to 20 million doses as it ramps up new manufacturing facilities.</p><p>A spokesman for the European Commission declined to comment on J&amp;J’s delivery schedules. The Commission coordinates EU talks with vaccine makers and has come under fire for its role in a vaccination strategy that has so far lagged behind those in Britain and the United States.</p><p>An internal document from the German health ministry dated Feb. 22, and a schedule published by the Italian health ministry on March 3, confirm that under the EU contract J&amp;J had committed to delivering around 55 million doses in the second quarter.</p><p>That includes about 10 million to Germany and 7.3 million to Italy. Supplies are expected to double in the third quarter, the two schedules show.</p><p>But J&amp;J has not yet provided figures on planned deliveries. “We don’t really know how much to expect,” the EU official said.</p><p><b>LATER START</b></p><p>Dutch Health Minister Hugo de Jonge told reporters he expected the company, which produces its COVID-19 vaccines for the EU in the Netherlands, to meet its second-quarter target of about three million doses for the country, although with limited deliveries in April and a ramp-up later in the quarter.</p><p>Ireland also expects J&amp;J to begin supplies a bit later in April than initially planned, with the largest deliveries at the end of the second quarter, the head of the country’s health service operator said on Tuesday, confirming earlier estimates for supplies through June.</p><p>EU countries raised questions earlier in the year about J&amp;J’s production network and contract with the EU, which would require it to send vaccines made at its Dutch factory to the United States for bottling before being shipped back to the EU.</p><p>A second EU official, also involved in talks with vaccine makers, said the bloc was trying to boost industrial capacity to bottle more shots in the EU, as part of plans to smooth out J&amp;J deliveries.</p><p>Actual deliveries have often diverged from contractual obligations as vaccine makers have struggled to ship millions of shots at breakneck pace amid the pandemic.</p><p>AstraZeneca cut planned first-quarter deliveries of its vaccine to the EU to 40 million doses from 90 million, and told the bloc second-quarter supplies would be halved. It later said it was striving to provide more shots from outside Europe.</p><p>Pfizer/BioNTech and Moderna have also faced delays in their deliveries to the EU, but kept their targets for the first quarter.</p><p>Under the contract with J&amp;J, the EU has also the option of ordering another 200 million doses, which if exercised would double its supply from the U.S. firm.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J 'under stress' to meet EU second-quarter vaccine supply goal - source</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J 'under stress' to meet EU second-quarter vaccine supply goal - source\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-09 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Johnson &amp; Johnson has told the European Union it is facing supply issues that may complicate plans to deliver 55 million doses of its COVID-19 vaccine to the bloc in the second quarter of the year, an EU official told Reuters.</p><p>Any delay would be a further blow to EU’s vaccination plans, which have been hampered by bumpy supplies from other vaccine makers and a slow rollout of shots in many member states.</p><p>J&amp;J told the EU last week that issues with the supply of vaccine ingredients and equipment meant it was “under stress” to meet the goal of delivering 55 million doses by the end of June, the EU official - who is directly involved in confidential talks with the U.S. company - told Reuters on condition of anonymity.</p><p>The official added the company had said it was not impossible to meet the goal, but that it showed caution.</p><p>J&amp;J’s vaccine, which requires only one dose for protection, is expected to be approved on March 11 for use in the EU by the bloc’s regulator. EU officials have said deliveries could start in April.</p><p>The company has committed to deliver 200 million doses of its vaccine to the bloc this year.</p><p>“Aligned with our agreement, we expect to begin supplying our commitment of 200 million doses to the European Union in the second quarter of 2021,” J&amp;J said in a statement, declining to comment on possible delays or the second-quarter target.</p><p>J&amp;J began rolling out its vaccine in the United States this month, with a target of delivering 100 million doses by the end of May, but has nearly halved its delivery forecasts for March to 20 million doses as it ramps up new manufacturing facilities.</p><p>A spokesman for the European Commission declined to comment on J&amp;J’s delivery schedules. The Commission coordinates EU talks with vaccine makers and has come under fire for its role in a vaccination strategy that has so far lagged behind those in Britain and the United States.</p><p>An internal document from the German health ministry dated Feb. 22, and a schedule published by the Italian health ministry on March 3, confirm that under the EU contract J&amp;J had committed to delivering around 55 million doses in the second quarter.</p><p>That includes about 10 million to Germany and 7.3 million to Italy. Supplies are expected to double in the third quarter, the two schedules show.</p><p>But J&amp;J has not yet provided figures on planned deliveries. “We don’t really know how much to expect,” the EU official said.</p><p><b>LATER START</b></p><p>Dutch Health Minister Hugo de Jonge told reporters he expected the company, which produces its COVID-19 vaccines for the EU in the Netherlands, to meet its second-quarter target of about three million doses for the country, although with limited deliveries in April and a ramp-up later in the quarter.</p><p>Ireland also expects J&amp;J to begin supplies a bit later in April than initially planned, with the largest deliveries at the end of the second quarter, the head of the country’s health service operator said on Tuesday, confirming earlier estimates for supplies through June.</p><p>EU countries raised questions earlier in the year about J&amp;J’s production network and contract with the EU, which would require it to send vaccines made at its Dutch factory to the United States for bottling before being shipped back to the EU.</p><p>A second EU official, also involved in talks with vaccine makers, said the bloc was trying to boost industrial capacity to bottle more shots in the EU, as part of plans to smooth out J&amp;J deliveries.</p><p>Actual deliveries have often diverged from contractual obligations as vaccine makers have struggled to ship millions of shots at breakneck pace amid the pandemic.</p><p>AstraZeneca cut planned first-quarter deliveries of its vaccine to the EU to 40 million doses from 90 million, and told the bloc second-quarter supplies would be halved. It later said it was striving to provide more shots from outside Europe.</p><p>Pfizer/BioNTech and Moderna have also faced delays in their deliveries to the EU, but kept their targets for the first quarter.</p><p>Under the contract with J&amp;J, the EU has also the option of ordering another 200 million doses, which if exercised would double its supply from the U.S. firm.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117128744","content_text":"Johnson & Johnson has told the European Union it is facing supply issues that may complicate plans to deliver 55 million doses of its COVID-19 vaccine to the bloc in the second quarter of the year, an EU official told Reuters.Any delay would be a further blow to EU’s vaccination plans, which have been hampered by bumpy supplies from other vaccine makers and a slow rollout of shots in many member states.J&J told the EU last week that issues with the supply of vaccine ingredients and equipment meant it was “under stress” to meet the goal of delivering 55 million doses by the end of June, the EU official - who is directly involved in confidential talks with the U.S. company - told Reuters on condition of anonymity.The official added the company had said it was not impossible to meet the goal, but that it showed caution.J&J’s vaccine, which requires only one dose for protection, is expected to be approved on March 11 for use in the EU by the bloc’s regulator. EU officials have said deliveries could start in April.The company has committed to deliver 200 million doses of its vaccine to the bloc this year.“Aligned with our agreement, we expect to begin supplying our commitment of 200 million doses to the European Union in the second quarter of 2021,” J&J said in a statement, declining to comment on possible delays or the second-quarter target.J&J began rolling out its vaccine in the United States this month, with a target of delivering 100 million doses by the end of May, but has nearly halved its delivery forecasts for March to 20 million doses as it ramps up new manufacturing facilities.A spokesman for the European Commission declined to comment on J&J’s delivery schedules. The Commission coordinates EU talks with vaccine makers and has come under fire for its role in a vaccination strategy that has so far lagged behind those in Britain and the United States.An internal document from the German health ministry dated Feb. 22, and a schedule published by the Italian health ministry on March 3, confirm that under the EU contract J&J had committed to delivering around 55 million doses in the second quarter.That includes about 10 million to Germany and 7.3 million to Italy. Supplies are expected to double in the third quarter, the two schedules show.But J&J has not yet provided figures on planned deliveries. “We don’t really know how much to expect,” the EU official said.LATER STARTDutch Health Minister Hugo de Jonge told reporters he expected the company, which produces its COVID-19 vaccines for the EU in the Netherlands, to meet its second-quarter target of about three million doses for the country, although with limited deliveries in April and a ramp-up later in the quarter.Ireland also expects J&J to begin supplies a bit later in April than initially planned, with the largest deliveries at the end of the second quarter, the head of the country’s health service operator said on Tuesday, confirming earlier estimates for supplies through June.EU countries raised questions earlier in the year about J&J’s production network and contract with the EU, which would require it to send vaccines made at its Dutch factory to the United States for bottling before being shipped back to the EU.A second EU official, also involved in talks with vaccine makers, said the bloc was trying to boost industrial capacity to bottle more shots in the EU, as part of plans to smooth out J&J deliveries.Actual deliveries have often diverged from contractual obligations as vaccine makers have struggled to ship millions of shots at breakneck pace amid the pandemic.AstraZeneca cut planned first-quarter deliveries of its vaccine to the EU to 40 million doses from 90 million, and told the bloc second-quarter supplies would be halved. It later said it was striving to provide more shots from outside Europe.Pfizer/BioNTech and Moderna have also faced delays in their deliveries to the EU, but kept their targets for the first quarter.Under the contract with J&J, the EU has also the option of ordering another 200 million doses, which if exercised would double its supply from the U.S. firm.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":731,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320265056,"gmtCreate":1615119214675,"gmtModify":1704778770806,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578051801807213","idStr":"3578051801807213"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/320265056","repostId":"1169596583","repostType":4,"repost":{"id":"1169596583","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614958557,"share":"https://ttm.financial/m/news/1169596583?lang=en_US&edition=fundamental","pubTime":"2021-03-05 23:35","market":"us","language":"en","title":"Palantir plunged more than 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169596583","media":"老虎资讯综合","summary":"(March 5)&nbsp;Palantir plunged more than 13%.","content":"<p>(March 5)&nbsp;Palantir plunged more than 13%.</p><p><img src=\"https://static.tigerbbs.com/13f756ec57cca85c31b6be070941d7c1\" tg-width=\"1059\" tg-height=\"499\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir plunged more than 13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir plunged more than 13%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-03-05 23:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(March 5)&nbsp;Palantir plunged more than 13%.</p><p><img src=\"https://static.tigerbbs.com/13f756ec57cca85c31b6be070941d7c1\" tg-width=\"1059\" tg-height=\"499\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169596583","content_text":"(March 5) Palantir plunged more than 13%.","news_type":1,"symbols_score_info":{"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":584,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":323711472,"gmtCreate":1615374866296,"gmtModify":1704781844010,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578051801807213","authorIdStr":"3578051801807213"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AYRO\">$AYRO, Inc.(AYRO)$</a>Lol","listText":"<a href=\"https://laohu8.com/S/AYRO\">$AYRO, Inc.(AYRO)$</a>Lol","text":"$AYRO, Inc.(AYRO)$Lol","images":[{"img":"https://static.tigerbbs.com/5a7a068e1f845f68e0209af558d44d34","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/323711472","isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3571882312755933","authorId":"3571882312755933","name":"Alexngo","avatar":"https://community-static.tradeup.com/news/223e039a4ee6d691503ce2aee951d200","crmLevel":11,"crmLevelSwitch":1,"idStr":"3571882312755933","authorIdStr":"3571882312755933"},"content":"Did you average when the price dip last few days?","text":"Did you average when the price dip last few days?","html":"Did you average when the price dip last few days?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":125013748,"gmtCreate":1624636375684,"gmtModify":1703842504505,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578051801807213","authorIdStr":"3578051801807213"},"themes":[],"htmlText":"Good to think about it!","listText":"Good to think about it!","text":"Good to think about it!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/125013748","repostId":"2146079086","repostType":4,"isVote":1,"tweetType":1,"viewCount":2827,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126867391,"gmtCreate":1624551772513,"gmtModify":1703840275896,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578051801807213","authorIdStr":"3578051801807213"},"themes":[],"htmlText":"That’s good news","listText":"That’s good news","text":"That’s good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126867391","repostId":"2145704596","repostType":4,"isVote":1,"tweetType":1,"viewCount":1781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323739872,"gmtCreate":1615373740896,"gmtModify":1704781827744,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578051801807213","authorIdStr":"3578051801807213"},"themes":[],"htmlText":"Must be careful","listText":"Must be careful","text":"Must be careful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/323739872","repostId":"2118269678","repostType":4,"repost":{"id":"2118269678","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1615370220,"share":"https://ttm.financial/m/news/2118269678?lang=en_US&edition=fundamental","pubTime":"2021-03-10 17:57","market":"hk","language":"en","title":"Investors blinded by over-optimism on vaccine rollout must see these risks, warns economist","url":"https://stock-news.laohu8.com/highlight/detail?id=2118269678","media":"Dow Jones","summary":"Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chines","content":"<blockquote>\n Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns this economist.\n</blockquote>\n<p>Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns a leading economist.</p>\n<p>Taimur Baig, chief economist at Singapore's DBS bank questions \"are we getting ahead of ourselves in beginning to look past the pandemic?\" Already, he notes, that bond yields have been firming \"in expectation of strong growth.\"</p>\n<p>He warns, in countries like the U.S., where vaccination pace has picked up, there will be a tendency among the population to let their guard down, and give up on wearing masks and social-distance requirements, causing a resurgence in infections.</p>\n<p>\"Outside of a few developed countries, the rate of vaccination is meager at the present stage\", he wrote in a Mar. 8 note. \"Vaccination-driven herd immunity is many months, if not years, away. Particularly worrisome is that with virus raging through the globe over the past year, a few potent variants have emerged.\"</p>\n<p>He says easing up on protective measures when variants are spreading could prove to be a huge mistake in the coming months, and says mask wearing and social distancing is absolutely critical.</p>\n<p>\"Otherwise, we are concerned that the SARS-Cov2 variants could end up making the market's normalization trades look highly premature,\" he warned.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors blinded by over-optimism on vaccine rollout must see these risks, warns economist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors blinded by over-optimism on vaccine rollout must see these risks, warns economist\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-03-10 17:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns this economist.\n</blockquote>\n<p>Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns a leading economist.</p>\n<p>Taimur Baig, chief economist at Singapore's DBS bank questions \"are we getting ahead of ourselves in beginning to look past the pandemic?\" Already, he notes, that bond yields have been firming \"in expectation of strong growth.\"</p>\n<p>He warns, in countries like the U.S., where vaccination pace has picked up, there will be a tendency among the population to let their guard down, and give up on wearing masks and social-distance requirements, causing a resurgence in infections.</p>\n<p>\"Outside of a few developed countries, the rate of vaccination is meager at the present stage\", he wrote in a Mar. 8 note. \"Vaccination-driven herd immunity is many months, if not years, away. Particularly worrisome is that with virus raging through the globe over the past year, a few potent variants have emerged.\"</p>\n<p>He says easing up on protective measures when variants are spreading could prove to be a huge mistake in the coming months, and says mask wearing and social distancing is absolutely critical.</p>\n<p>\"Otherwise, we are concerned that the SARS-Cov2 variants could end up making the market's normalization trades look highly premature,\" he warned.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2118269678","content_text":"Enthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns this economist.\n\nEnthusiasm for President Joe Biden's coronavirus relief package, the rollout of vaccines, and Chinese growth have made investors blind to these risks, warns a leading economist.\nTaimur Baig, chief economist at Singapore's DBS bank questions \"are we getting ahead of ourselves in beginning to look past the pandemic?\" Already, he notes, that bond yields have been firming \"in expectation of strong growth.\"\nHe warns, in countries like the U.S., where vaccination pace has picked up, there will be a tendency among the population to let their guard down, and give up on wearing masks and social-distance requirements, causing a resurgence in infections.\n\"Outside of a few developed countries, the rate of vaccination is meager at the present stage\", he wrote in a Mar. 8 note. \"Vaccination-driven herd immunity is many months, if not years, away. Particularly worrisome is that with virus raging through the globe over the past year, a few potent variants have emerged.\"\nHe says easing up on protective measures when variants are spreading could prove to be a huge mistake in the coming months, and says mask wearing and social distancing is absolutely critical.\n\"Otherwise, we are concerned that the SARS-Cov2 variants could end up making the market's normalization trades look highly premature,\" he warned.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899885493,"gmtCreate":1628173737712,"gmtModify":1703502597837,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578051801807213","authorIdStr":"3578051801807213"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BITF\">$Bitfarms Ltd.(BITF)$</a>Set the wrong buy limit but I guess 10% profit is still better than nothing&nbsp;","listText":"<a href=\"https://laohu8.com/S/BITF\">$Bitfarms Ltd.(BITF)$</a>Set the wrong buy limit but I guess 10% profit is still better than nothing&nbsp;","text":"$Bitfarms Ltd.(BITF)$Set the wrong buy limit but I guess 10% profit is still better than nothing","images":[{"img":"https://static.tigerbbs.com/803c9b4ab887314e0ebb7722c4770c51","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899885493","isVote":1,"tweetType":1,"viewCount":1366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":322982142,"gmtCreate":1615767483186,"gmtModify":1704786162668,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578051801807213","authorIdStr":"3578051801807213"},"themes":[],"htmlText":"Indeed this will be interesting to watch!","listText":"Indeed this will be interesting to watch!","text":"Indeed this will be interesting to watch!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322982142","repostId":"1155155337","repostType":4,"repost":{"id":"1155155337","kind":"news","pubTimestamp":1615765765,"share":"https://ttm.financial/m/news/1155155337?lang=en_US&edition=fundamental","pubTime":"2021-03-15 07:49","market":"us","language":"en","title":"Pinduoduo, Nike,AMD, Lennar, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1155155337","media":"Barrons","summary":"The earnings calendar is sparse this week. The few major companies reporting include home-builder Le","content":"<p>The earnings calendar is sparse this week. The few major companies reporting include home-builder&nbsp;Lennaron Tuesday and Pinduoduo,business-services firm&nbsp;Cintason Wednesday. Thursday will be more interesting as&nbsp;Nike,FedEx,and&nbsp;Dollar General&nbsp;report.Advanced Micro Deviceswill also host an event on Monday to unveil new chips.</p><p>The economic calendar this week will be more eventful. The Federal Reserve’s monetary policy committee’s March meeting concludes on Wednesday, with its latest decision&nbsp;and a press conference from chairman Jerome Powell coming that afternoon. TheBank of Japanwill announce its latest policy move on Friday.</p><p>Economic data out this week includes the Census Bureau’s retail-sales data for February on Tuesday, along with the National Association of Home Builders’ NAHB/Wells FargoHousing Market index for March. Then on Wednesday, the Census Bureau reports residential construction data for February. And on Thursday, the Conference Board releases its Leading Economic index for February.</p><p><b>Monday 3/15</b></p><p>Advanced Micro Devices hosts a conference call in conjunction with the launch of its third-generation EPYC processors. Senior management, including CEO Lisa Su, will give presentations on the new chips. AMD shares doubled last year, making them the 10th best performers in the&nbsp;S&amp;P 500.</p><p><b>The Federal Reserve</b>&nbsp;Bank of New York releases its Empire State Manufacturing Survey for March. The consensus estimate is for a 16.5 reading, versus February’s 12.1. The index has had eight consecutive months of positive readings, indicating improving conditions in the region’s manufacturing sector.</p><p><b>Tuesday 3/16</b></p><p><b>CrowdStrike Holdings</b>&nbsp;and Lennar report quarterly results.</p><p><b>The National Association</b>&nbsp;of Home Builders releases its NAHB/Wells Fargo Housing Market index for March. Economists forecast an 84 reading, even with February’s. The index is off its all-time high of 90, set last November, but home builders remain bullish on the housing market.</p><p><b>The Census Bureau</b>&nbsp;reports retail-sales data for February. Expectations are for a 0.7% month-over-month decline, after a 5.3% jump in January. Excluding autos, spending is seen edging down 0.1%, compared with a 5.9% increase previously.</p><p><b>Wednesday 3/17</b></p><p><b>The Federal Open Market Committee</b>announces its monetary-policy decision. The Federal Reserve has stressed that it will keep interest rates near zero through 2023, but might tweak its bond-buying program.</p><p><b>Cintas and Five Below</b>&nbsp;report earnings.</p><p><b>Pinduoduo</b>&nbsp;report earnings.</p><p><b>The Census Bureau</b>&nbsp;reports residential construction data for February. The consensus call is for a seasonally adjusted annual rate of 1.57 million housing starts, in line with the January figure. Housing starts remain just off their post-financial-crisis peak.</p><p><b>Thursday 3/18</b></p><p>Accenture,Dollar General, FedEx, and Nike hold conference calls to discuss quarterly results.</p><p><b>The Conference Board</b>&nbsp;releases its Leading Economic index for February. Economists forecast a 0.4% monthly rise. The LEI has increased every month since last April, though the rate of growth has slowed since the third quarter of last year.</p><p><b>The Department of Labor</b>&nbsp;reports jobless claims for the week ended on March 13. This past week’s total of 712,000claims was the second lowest since the beginning of the Covid-19 pandemic.</p><p><b>Friday 3/19</b></p><p><b>The Bank of Japan</b>&nbsp;announces its monetary-policy decision after a two-day meeting. The central bank is widely expected to keep its key short-term interest rate unchanged, at a negative 0.1%. The BOJ also will review its policy tools during the meeting.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pinduoduo, Nike,AMD, Lennar, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPinduoduo, Nike,AMD, Lennar, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 07:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/nike-fedex-amd-lennar-and-other-stocks-for-investors-to-watch-this-week-51615748409?mod=hp_LEAD_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The earnings calendar is sparse this week. The few major companies reporting include home-builder Lennaron Tuesday and Pinduoduo,business-services firm Cintason Wednesday. Thursday will be more ...</p>\n\n<a href=\"https://www.barrons.com/articles/nike-fedex-amd-lennar-and-other-stocks-for-investors-to-watch-this-week-51615748409?mod=hp_LEAD_2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FDX":"联邦快递","PDD":"拼多多","NKE":"耐克","AMD":"美国超微公司"},"source_url":"https://www.barrons.com/articles/nike-fedex-amd-lennar-and-other-stocks-for-investors-to-watch-this-week-51615748409?mod=hp_LEAD_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155155337","content_text":"The earnings calendar is sparse this week. The few major companies reporting include home-builder Lennaron Tuesday and Pinduoduo,business-services firm Cintason Wednesday. Thursday will be more interesting as Nike,FedEx,and Dollar General report.Advanced Micro Deviceswill also host an event on Monday to unveil new chips.The economic calendar this week will be more eventful. The Federal Reserve’s monetary policy committee’s March meeting concludes on Wednesday, with its latest decision and a press conference from chairman Jerome Powell coming that afternoon. TheBank of Japanwill announce its latest policy move on Friday.Economic data out this week includes the Census Bureau’s retail-sales data for February on Tuesday, along with the National Association of Home Builders’ NAHB/Wells FargoHousing Market index for March. Then on Wednesday, the Census Bureau reports residential construction data for February. And on Thursday, the Conference Board releases its Leading Economic index for February.Monday 3/15Advanced Micro Devices hosts a conference call in conjunction with the launch of its third-generation EPYC processors. Senior management, including CEO Lisa Su, will give presentations on the new chips. AMD shares doubled last year, making them the 10th best performers in the S&P 500.The Federal Reserve Bank of New York releases its Empire State Manufacturing Survey for March. The consensus estimate is for a 16.5 reading, versus February’s 12.1. The index has had eight consecutive months of positive readings, indicating improving conditions in the region’s manufacturing sector.Tuesday 3/16CrowdStrike Holdings and Lennar report quarterly results.The National Association of Home Builders releases its NAHB/Wells Fargo Housing Market index for March. Economists forecast an 84 reading, even with February’s. The index is off its all-time high of 90, set last November, but home builders remain bullish on the housing market.The Census Bureau reports retail-sales data for February. Expectations are for a 0.7% month-over-month decline, after a 5.3% jump in January. Excluding autos, spending is seen edging down 0.1%, compared with a 5.9% increase previously.Wednesday 3/17The Federal Open Market Committeeannounces its monetary-policy decision. The Federal Reserve has stressed that it will keep interest rates near zero through 2023, but might tweak its bond-buying program.Cintas and Five Below report earnings.Pinduoduo report earnings.The Census Bureau reports residential construction data for February. The consensus call is for a seasonally adjusted annual rate of 1.57 million housing starts, in line with the January figure. Housing starts remain just off their post-financial-crisis peak.Thursday 3/18Accenture,Dollar General, FedEx, and Nike hold conference calls to discuss quarterly results.The Conference Board releases its Leading Economic index for February. Economists forecast a 0.4% monthly rise. The LEI has increased every month since last April, though the rate of growth has slowed since the third quarter of last year.The Department of Labor reports jobless claims for the week ended on March 13. This past week’s total of 712,000claims was the second lowest since the beginning of the Covid-19 pandemic.Friday 3/19The Bank of Japan announces its monetary-policy decision after a two-day meeting. The central bank is widely expected to keep its key short-term interest rate unchanged, at a negative 0.1%. The BOJ also will review its policy tools during the meeting.","news_type":1,"symbols_score_info":{"NKE":0.9,"AMD":0.9,"PDD":0.9,"FDX":0.9}},"isVote":1,"tweetType":1,"viewCount":1387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328540228,"gmtCreate":1615543494764,"gmtModify":1704784342812,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578051801807213","authorIdStr":"3578051801807213"},"themes":[],"htmlText":"Yes indeed that is true","listText":"Yes indeed that is true","text":"Yes indeed that is true","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328540228","repostId":"1155506399","repostType":4,"isVote":1,"tweetType":1,"viewCount":1808,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":321669546,"gmtCreate":1615429632285,"gmtModify":1704782657766,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578051801807213","authorIdStr":"3578051801807213"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>Was a little disappointed that we didn’t hold the slope up yesterday but I guess it would be good to spend more time in consolidation mode. It could be difficult to see but will be healthier in the long run. Hoping for more sustained upside action in the months to come!","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>Was a little disappointed that we didn’t hold the slope up yesterday but I guess it would be good to spend more time in consolidation mode. It could be difficult to see but will be healthier in the long run. Hoping for more sustained upside action in the months to come!","text":"$Sea Ltd(SE)$Was a little disappointed that we didn’t hold the slope up yesterday but I guess it would be good to spend more time in consolidation mode. It could be difficult to see but will be healthier in the long run. Hoping for more sustained upside action in the months to come!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/321669546","isVote":1,"tweetType":1,"viewCount":1505,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323320685,"gmtCreate":1615303982947,"gmtModify":1704780943187,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578051801807213","authorIdStr":"3578051801807213"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>My only regret is not buying when Shopee launched in Singapore a few years ago. They’re actually doing quite well in terms of public sentiment and I think they’ll do well compared to direct competitors&nbsp;","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>My only regret is not buying when Shopee launched in Singapore a few years ago. They’re actually doing quite well in terms of public sentiment and I think they’ll do well compared to direct competitors&nbsp;","text":"$Sea Ltd(SE)$My only regret is not buying when Shopee launched in Singapore a few years ago. They’re actually doing quite well in terms of public sentiment and I think they’ll do well compared to direct competitors","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323320685","isVote":1,"tweetType":1,"viewCount":581,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323366601,"gmtCreate":1615303798003,"gmtModify":1704780934099,"author":{"id":"3578051801807213","authorId":"3578051801807213","name":"Fishingboy","avatar":"https://static.tigerbbs.com/f0ff6d321e13a5a7b419cda3219c1b1f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578051801807213","authorIdStr":"3578051801807213"},"themes":[],"htmlText":"Go J&amp;J!","listText":"Go J&amp;J!","text":"Go J&J!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/323366601","repostId":"1117128744","repostType":4,"repost":{"id":"1117128744","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1615298116,"share":"https://ttm.financial/m/news/1117128744?lang=en_US&edition=fundamental","pubTime":"2021-03-09 21:55","market":"us","language":"en","title":"J&J 'under stress' to meet EU second-quarter vaccine supply goal - source","url":"https://stock-news.laohu8.com/highlight/detail?id=1117128744","media":"Reuters","summary":"Johnson & Johnson has told the European Union it is facing supply issues that may complicate plans t","content":"<p>Johnson &amp; Johnson has told the European Union it is facing supply issues that may complicate plans to deliver 55 million doses of its COVID-19 vaccine to the bloc in the second quarter of the year, an EU official told Reuters.</p><p>Any delay would be a further blow to EU’s vaccination plans, which have been hampered by bumpy supplies from other vaccine makers and a slow rollout of shots in many member states.</p><p>J&amp;J told the EU last week that issues with the supply of vaccine ingredients and equipment meant it was “under stress” to meet the goal of delivering 55 million doses by the end of June, the EU official - who is directly involved in confidential talks with the U.S. company - told Reuters on condition of anonymity.</p><p>The official added the company had said it was not impossible to meet the goal, but that it showed caution.</p><p>J&amp;J’s vaccine, which requires only one dose for protection, is expected to be approved on March 11 for use in the EU by the bloc’s regulator. EU officials have said deliveries could start in April.</p><p>The company has committed to deliver 200 million doses of its vaccine to the bloc this year.</p><p>“Aligned with our agreement, we expect to begin supplying our commitment of 200 million doses to the European Union in the second quarter of 2021,” J&amp;J said in a statement, declining to comment on possible delays or the second-quarter target.</p><p>J&amp;J began rolling out its vaccine in the United States this month, with a target of delivering 100 million doses by the end of May, but has nearly halved its delivery forecasts for March to 20 million doses as it ramps up new manufacturing facilities.</p><p>A spokesman for the European Commission declined to comment on J&amp;J’s delivery schedules. The Commission coordinates EU talks with vaccine makers and has come under fire for its role in a vaccination strategy that has so far lagged behind those in Britain and the United States.</p><p>An internal document from the German health ministry dated Feb. 22, and a schedule published by the Italian health ministry on March 3, confirm that under the EU contract J&amp;J had committed to delivering around 55 million doses in the second quarter.</p><p>That includes about 10 million to Germany and 7.3 million to Italy. Supplies are expected to double in the third quarter, the two schedules show.</p><p>But J&amp;J has not yet provided figures on planned deliveries. “We don’t really know how much to expect,” the EU official said.</p><p><b>LATER START</b></p><p>Dutch Health Minister Hugo de Jonge told reporters he expected the company, which produces its COVID-19 vaccines for the EU in the Netherlands, to meet its second-quarter target of about three million doses for the country, although with limited deliveries in April and a ramp-up later in the quarter.</p><p>Ireland also expects J&amp;J to begin supplies a bit later in April than initially planned, with the largest deliveries at the end of the second quarter, the head of the country’s health service operator said on Tuesday, confirming earlier estimates for supplies through June.</p><p>EU countries raised questions earlier in the year about J&amp;J’s production network and contract with the EU, which would require it to send vaccines made at its Dutch factory to the United States for bottling before being shipped back to the EU.</p><p>A second EU official, also involved in talks with vaccine makers, said the bloc was trying to boost industrial capacity to bottle more shots in the EU, as part of plans to smooth out J&amp;J deliveries.</p><p>Actual deliveries have often diverged from contractual obligations as vaccine makers have struggled to ship millions of shots at breakneck pace amid the pandemic.</p><p>AstraZeneca cut planned first-quarter deliveries of its vaccine to the EU to 40 million doses from 90 million, and told the bloc second-quarter supplies would be halved. It later said it was striving to provide more shots from outside Europe.</p><p>Pfizer/BioNTech and Moderna have also faced delays in their deliveries to the EU, but kept their targets for the first quarter.</p><p>Under the contract with J&amp;J, the EU has also the option of ordering another 200 million doses, which if exercised would double its supply from the U.S. firm.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J 'under stress' to meet EU second-quarter vaccine supply goal - source</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J 'under stress' to meet EU second-quarter vaccine supply goal - source\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-09 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Johnson &amp; Johnson has told the European Union it is facing supply issues that may complicate plans to deliver 55 million doses of its COVID-19 vaccine to the bloc in the second quarter of the year, an EU official told Reuters.</p><p>Any delay would be a further blow to EU’s vaccination plans, which have been hampered by bumpy supplies from other vaccine makers and a slow rollout of shots in many member states.</p><p>J&amp;J told the EU last week that issues with the supply of vaccine ingredients and equipment meant it was “under stress” to meet the goal of delivering 55 million doses by the end of June, the EU official - who is directly involved in confidential talks with the U.S. company - told Reuters on condition of anonymity.</p><p>The official added the company had said it was not impossible to meet the goal, but that it showed caution.</p><p>J&amp;J’s vaccine, which requires only one dose for protection, is expected to be approved on March 11 for use in the EU by the bloc’s regulator. EU officials have said deliveries could start in April.</p><p>The company has committed to deliver 200 million doses of its vaccine to the bloc this year.</p><p>“Aligned with our agreement, we expect to begin supplying our commitment of 200 million doses to the European Union in the second quarter of 2021,” J&amp;J said in a statement, declining to comment on possible delays or the second-quarter target.</p><p>J&amp;J began rolling out its vaccine in the United States this month, with a target of delivering 100 million doses by the end of May, but has nearly halved its delivery forecasts for March to 20 million doses as it ramps up new manufacturing facilities.</p><p>A spokesman for the European Commission declined to comment on J&amp;J’s delivery schedules. The Commission coordinates EU talks with vaccine makers and has come under fire for its role in a vaccination strategy that has so far lagged behind those in Britain and the United States.</p><p>An internal document from the German health ministry dated Feb. 22, and a schedule published by the Italian health ministry on March 3, confirm that under the EU contract J&amp;J had committed to delivering around 55 million doses in the second quarter.</p><p>That includes about 10 million to Germany and 7.3 million to Italy. Supplies are expected to double in the third quarter, the two schedules show.</p><p>But J&amp;J has not yet provided figures on planned deliveries. “We don’t really know how much to expect,” the EU official said.</p><p><b>LATER START</b></p><p>Dutch Health Minister Hugo de Jonge told reporters he expected the company, which produces its COVID-19 vaccines for the EU in the Netherlands, to meet its second-quarter target of about three million doses for the country, although with limited deliveries in April and a ramp-up later in the quarter.</p><p>Ireland also expects J&amp;J to begin supplies a bit later in April than initially planned, with the largest deliveries at the end of the second quarter, the head of the country’s health service operator said on Tuesday, confirming earlier estimates for supplies through June.</p><p>EU countries raised questions earlier in the year about J&amp;J’s production network and contract with the EU, which would require it to send vaccines made at its Dutch factory to the United States for bottling before being shipped back to the EU.</p><p>A second EU official, also involved in talks with vaccine makers, said the bloc was trying to boost industrial capacity to bottle more shots in the EU, as part of plans to smooth out J&amp;J deliveries.</p><p>Actual deliveries have often diverged from contractual obligations as vaccine makers have struggled to ship millions of shots at breakneck pace amid the pandemic.</p><p>AstraZeneca cut planned first-quarter deliveries of its vaccine to the EU to 40 million doses from 90 million, and told the bloc second-quarter supplies would be halved. It later said it was striving to provide more shots from outside Europe.</p><p>Pfizer/BioNTech and Moderna have also faced delays in their deliveries to the EU, but kept their targets for the first quarter.</p><p>Under the contract with J&amp;J, the EU has also the option of ordering another 200 million doses, which if exercised would double its supply from the U.S. firm.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117128744","content_text":"Johnson & Johnson has told the European Union it is facing supply issues that may complicate plans to deliver 55 million doses of its COVID-19 vaccine to the bloc in the second quarter of the year, an EU official told Reuters.Any delay would be a further blow to EU’s vaccination plans, which have been hampered by bumpy supplies from other vaccine makers and a slow rollout of shots in many member states.J&J told the EU last week that issues with the supply of vaccine ingredients and equipment meant it was “under stress” to meet the goal of delivering 55 million doses by the end of June, the EU official - who is directly involved in confidential talks with the U.S. company - told Reuters on condition of anonymity.The official added the company had said it was not impossible to meet the goal, but that it showed caution.J&J’s vaccine, which requires only one dose for protection, is expected to be approved on March 11 for use in the EU by the bloc’s regulator. EU officials have said deliveries could start in April.The company has committed to deliver 200 million doses of its vaccine to the bloc this year.“Aligned with our agreement, we expect to begin supplying our commitment of 200 million doses to the European Union in the second quarter of 2021,” J&J said in a statement, declining to comment on possible delays or the second-quarter target.J&J began rolling out its vaccine in the United States this month, with a target of delivering 100 million doses by the end of May, but has nearly halved its delivery forecasts for March to 20 million doses as it ramps up new manufacturing facilities.A spokesman for the European Commission declined to comment on J&J’s delivery schedules. The Commission coordinates EU talks with vaccine makers and has come under fire for its role in a vaccination strategy that has so far lagged behind those in Britain and the United States.An internal document from the German health ministry dated Feb. 22, and a schedule published by the Italian health ministry on March 3, confirm that under the EU contract J&J had committed to delivering around 55 million doses in the second quarter.That includes about 10 million to Germany and 7.3 million to Italy. Supplies are expected to double in the third quarter, the two schedules show.But J&J has not yet provided figures on planned deliveries. “We don’t really know how much to expect,” the EU official said.LATER STARTDutch Health Minister Hugo de Jonge told reporters he expected the company, which produces its COVID-19 vaccines for the EU in the Netherlands, to meet its second-quarter target of about three million doses for the country, although with limited deliveries in April and a ramp-up later in the quarter.Ireland also expects J&J to begin supplies a bit later in April than initially planned, with the largest deliveries at the end of the second quarter, the head of the country’s health service operator said on Tuesday, confirming earlier estimates for supplies through June.EU countries raised questions earlier in the year about J&J’s production network and contract with the EU, which would require it to send vaccines made at its Dutch factory to the United States for bottling before being shipped back to the EU.A second EU official, also involved in talks with vaccine makers, said the bloc was trying to boost industrial capacity to bottle more shots in the EU, as part of plans to smooth out J&J deliveries.Actual deliveries have often diverged from contractual obligations as vaccine makers have struggled to ship millions of shots at breakneck pace amid the pandemic.AstraZeneca cut planned first-quarter deliveries of its vaccine to the EU to 40 million doses from 90 million, and told the bloc second-quarter supplies would be halved. It later said it was striving to provide more shots from outside Europe.Pfizer/BioNTech and Moderna have also faced delays in their deliveries to the EU, but kept their targets for the first quarter.Under the contract with J&J, the EU has also the option of ordering another 200 million doses, which if exercised would double its supply from the U.S. firm.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":731,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}